ES2192264T3 - Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina. - Google Patents

Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina.

Info

Publication number
ES2192264T3
ES2192264T3 ES97907237T ES97907237T ES2192264T3 ES 2192264 T3 ES2192264 T3 ES 2192264T3 ES 97907237 T ES97907237 T ES 97907237T ES 97907237 T ES97907237 T ES 97907237T ES 2192264 T3 ES2192264 T3 ES 2192264T3
Authority
ES
Spain
Prior art keywords
piperazinil
etil
ona
indol
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97907237T
Other languages
English (en)
Spanish (es)
Inventor
Frank R Busch
Carol A Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2192264T3 publication Critical patent/ES2192264T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES97907237T 1996-05-07 1997-03-26 Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina. Expired - Lifetime ES2192264T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
ES2192264T3 true ES2192264T3 (es) 2003-10-01

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97907237T Expired - Lifetime ES2192264T3 (es) 1996-05-07 1997-03-26 Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina.

Country Status (45)

Country Link
US (1) US6110918A (enExample)
EP (1) EP0904273B1 (enExample)
JP (1) JP3102896B2 (enExample)
KR (1) KR100333214B1 (enExample)
CN (1) CN1092658C (enExample)
AP (1) AP838A (enExample)
AR (1) AR007003A1 (enExample)
AT (1) ATE236902T1 (enExample)
AU (1) AU730856C (enExample)
BG (1) BG63601B1 (enExample)
BR (1) BR9708932A (enExample)
CA (1) CA2252895C (enExample)
CO (1) CO4940465A1 (enExample)
CZ (1) CZ289216B6 (enExample)
DE (1) DE69720719T2 (enExample)
DK (1) DK0904273T3 (enExample)
DZ (1) DZ2221A1 (enExample)
EA (1) EA001180B1 (enExample)
EG (1) EG24401A (enExample)
ES (1) ES2192264T3 (enExample)
GT (1) GT199700042A (enExample)
HN (1) HN1997000040A (enExample)
HR (1) HRP970235B1 (enExample)
HU (1) HU229057B1 (enExample)
ID (1) ID17504A (enExample)
IL (1) IL126590A (enExample)
IS (1) IS2301B (enExample)
MA (1) MA26427A1 (enExample)
ME (1) ME00901B (enExample)
MY (1) MY128051A (enExample)
NO (1) NO312513B1 (enExample)
NZ (2) NZ508303A (enExample)
OA (1) OA10908A (enExample)
PL (1) PL188164B1 (enExample)
PT (1) PT904273E (enExample)
SI (1) SI0904273T1 (enExample)
SK (1) SK282674B6 (enExample)
TN (1) TNSN97073A1 (enExample)
TR (1) TR199802241T2 (enExample)
TW (1) TW427989B (enExample)
UA (1) UA47467C2 (enExample)
UY (1) UY24543A1 (enExample)
WO (1) WO1997042190A1 (enExample)
YU (1) YU49398B (enExample)
ZA (1) ZA973875B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2250001A1 (es) * 2004-09-29 2006-04-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
DK0985414T3 (da) * 1998-05-26 2003-12-29 Pfizer Prod Inc Lægemiddel til behandling af glaukome og iskæmisk retinopati
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
TR200201617T2 (tr) 1999-12-23 2002-10-21 Pfizer Products Inc. Kuvvetlendirilmiş ilaç konsantrasyonları sağlayan farmasötik kompozisyonlar
DE60133596D1 (de) * 2000-06-02 2008-05-21 Pfizer Prod Inc S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
CA2525323A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
MXPA05012392A (es) * 2003-05-16 2006-02-02 Pfizer Prod Inc Tratamientos de ansiedad con ziprasidona.
CA2525866A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
KR20060015750A (ko) * 2003-06-03 2006-02-20 테바 파마슈티컬 인더스트리즈 리미티드 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
AR046811A1 (es) * 2003-09-02 2005-12-28 Imran Ahmed Formas de dosificacion oral de ziprasidona de liberacion sostenida
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
CN1934108A (zh) * 2003-12-18 2007-03-21 特瓦制药工业有限公司 齐拉西酮碱的多晶型b2
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
US20080312254A1 (en) * 2004-02-27 2008-12-18 Ranbaxy Laboratories Limited Process for the Preparation of Ziprasidone
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
WO2006086779A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Amorphous ziprasidone mesylate
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
US20080286373A1 (en) * 2007-05-18 2008-11-20 Palepu Nageswara R Ziprasidone formulations
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2250001A1 (es) * 2004-09-29 2006-04-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.

Also Published As

Publication number Publication date
HRP970235B1 (en) 2002-08-31
HU229057B1 (en) 2013-07-29
SK282674B6 (sk) 2002-11-06
NO985193L (no) 1998-11-06
DE69720719T2 (de) 2003-11-06
HK1017893A1 (en) 1999-12-03
CA2252895C (en) 2002-08-20
ID17504A (id) 1998-01-08
BR9708932A (pt) 1999-08-03
OA10908A (en) 2001-10-26
IL126590A (en) 2001-11-25
NO985193D0 (no) 1998-11-06
CA2252895A1 (en) 1997-11-13
MY128051A (en) 2007-01-31
IS4878A (is) 1998-10-23
PT904273E (pt) 2003-06-30
CN1092658C (zh) 2002-10-16
NZ332219A (en) 2005-02-25
HRP970235A2 (en) 1998-06-30
HUP9902808A2 (hu) 2000-03-28
WO1997042190A1 (en) 1997-11-13
PL329880A1 (en) 1999-04-12
AU730856C (en) 2001-11-15
ME00901B (me) 2005-11-28
JP3102896B2 (ja) 2000-10-23
ZA973875B (en) 1998-11-06
UA47467C2 (uk) 2002-07-15
MA26427A1 (fr) 2004-12-20
AU1936897A (en) 1997-11-26
AR007003A1 (es) 1999-10-13
PL188164B1 (pl) 2004-12-31
DE69720719D1 (de) 2003-05-15
UY24543A1 (es) 2000-09-29
GT199700042A (es) 1998-10-02
YU17397A (sh) 2000-10-30
NZ508303A (en) 2001-07-27
DZ2221A1 (fr) 2002-12-03
TW427989B (en) 2001-04-01
EP0904273B1 (en) 2003-04-09
CZ289216B6 (cs) 2001-12-12
YU49398B (sh) 2005-11-28
EP0904273A1 (en) 1999-03-31
TR199802241T2 (enExample) 1999-02-22
DK0904273T3 (da) 2003-07-07
ATE236902T1 (de) 2003-04-15
AU730856B2 (en) 2001-03-15
SK150598A3 (en) 2000-03-13
IS2301B (is) 2007-10-15
NO312513B1 (no) 2002-05-21
BG102893A (en) 1999-09-30
KR100333214B1 (ko) 2002-06-20
IL126590A0 (en) 1999-08-17
HN1997000040A (es) 1997-06-05
KR20000010822A (ko) 2000-02-25
US6110918A (en) 2000-08-29
BG63601B1 (bg) 2002-06-28
AP9700978A0 (en) 1997-07-31
EG24401A (en) 2009-04-29
EA199800909A1 (ru) 1999-04-29
TNSN97073A1 (fr) 2005-03-15
EA001180B1 (ru) 2000-10-30
CZ349498A3 (cs) 1999-09-15
SI0904273T1 (en) 2003-08-31
CN1216990A (zh) 1999-05-19
AP838A (en) 2000-05-03
HUP9902808A3 (en) 2000-04-28
JPH11509865A (ja) 1999-08-31
CO4940465A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
ES2192264T3 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina.
EA199800912A1 (ru) Дигидратная соль мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2(1н)-индол-2-она, фармацевтическая композиция и способ лечения психотического расстройства
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
EA200870376A1 (ru) Бензотиазолы, обладающие активностью по отношению к h3-рецептору гистамина
CO5550451A2 (es) Derivados de 3-(sulfonamidoetil)-indol para uso como mimeti- cos de glucocorticoides en el tratamiento de enfermedades inflamatorias, alergicas y proliferativas
BR0014279A (pt) Derivados de piperazina como antagonistas 5-ht1b
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
DK1288205T3 (da) Nye phenylalanin-derivater
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
DE60121461D1 (de) Kondensierte pyridoindolderivate
BR0313385A (pt) Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
ES2166046T3 (es) Derivados de arilacrilamida como agonistas o antagonistas de 5ht1.
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2
PE20020603A1 (es) Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy)
ES2180573T3 (es) Uso de derivados de indol como antagonistas de 5ht1.
DE60112960D1 (de) Kondensierte pyridoindolderivate
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
YU44301A (sh) 5ht1 antagonisti za antidepresantnu terapiju
DE69819742D1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
SE0002729D0 (sv) Novel compound form
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
AR044720A1 (es) Una sulfonamida heterociclica, su uso, un proceso para prepararla, una composicion farmaceutica que la comprende, y compuestos utiles como intermediari0s
PE20020557A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 para tratar la disfuncion sexual
BR0318659A (pt) derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores
AR010289A1 (es) Derivados de piperidina, procedimiento para su preparacion, formulaciones farmaceuticas que contienen los derivados y su uso en el tratamiento dedesordenes psicoticos